nice!innovations GmbH

Presentation Time and Location
on 25th, during Rising European Stars Session (from 16.15 to 17.15)
Company Profile

The “external fixators” (FixEx) used to date have already provided the outstanding service of stabilizing bone fractures in case of serious injuries, open bone fractures and severe joint fractures for decades. With all “external fixator” systems, four to six bone pins are screwed through the skin and into the bone. A fixation device (the actual “external fixator”) is then attached to these bone pins externally. Very often so-called “trauma fixators” are then removed after a few days or weeks once the patient’s overall condition has stabilized. The bone fracture is then definitively stabilized using a plate and screws or intramedullary nails. However, mounting the “external fixator” systems that are currently on the market is enormously time-consuming and error-prone and can only be reliably implemented by experienced orthopedic surgeons.  

The technical invention “snake FX” by the Erlangen-based startup nice!innovations GmbH has profoundly revolutionized the “external fixator” and its use in orthopedics and accident surgery. It is a conceptually completely new and an already well-developed product that enables an enormously clever, incomparably fast, incredibly simple method for stabilization of bone fractures by means of an unprecedented “snake principle”. Its “one-step rapid fixation technology” allows “snakeFX” to both fix the external fixator to the bone pins and stabilize the “FixEx” in a single step! Using traditional external fixator systems, both tasks involved time-consuming and error-prone mounting operations. Patents for “snake FX” have already been awarded for Europe, US, Brazil and Japan!

Precisely these unique selling points are leveraged when it comes to distribution: An initial estimate from Switzerland illustrates the high cost-saving potential combined with a dramatic increase in the quality of care for the patient. In Switzerland, one minute in the operating room costs 80 CHF. It takes trained orthopedic and trauma surgeons anywhere from 60 to 120 minutes for mounting and to make fine adjustments. The “snakeFX” aims to reduce this time to about 15 minutes.    

nice!innovations GmbH is currently developing the “snakeFX” into an approved product that is ready for series production. A crowd-financing campaign on www.aescuvest.de had collected more than 260,000 euros for this purpose as of February 2016 (in the form of subordinated loans). Following successful prototyping (expected in Q3/2017), snakeFX can obtain CE approval and be prepared for series production (target Q3/2018) within 9 to 12 months. The service provider for carrying out CE certification (Risk Class 1s; assessment by the “Notified Bodies” is available) has already been commissioned; a usability study with trauma surgeons, prototype-testing in a certified testing laboratory and a clinical trial are currently being conceptualized and implemented. An investor or strategic partner is being sought for the subsequent international commercialization of “snakeFX”.

Company Type
Jörg Trinkwalter
Jörg Trinkwalter
CEO 
Conference attendance
Biography

Jörg Trinkwalter is a member of the Executive Board of the cluster management organization Medical Valley Europäische Metropolregion Nürnberg (EMN) e.V., as well as registered manager of the incubator Medical Valley Center in Erlangen/Germany. Medical Valley EMN is considered as one of the most dynamic medical technology regions worldwide and was awarded national cluster of excellence by the German Ministry of Education and Research in 2010. In 2015 Jörg Trinkwalter co-founded the two medical technology startup companies nice!innovations GmbH and TBrace GmbH in the orthopedic area and acts as CEO of these companies. nice!innovations GmbH raised 262.000 € in 2016 via a crowdfinancing campaign on www.aescuvest.de in order to develop the new fixateur externe-concept “snakeFX” market-ready.   

Novo Holdings A/S

Dr Jørgen Søberg Petersen
Venture Partner 
Conference attendance
Nanna Lüneborg
Nanna Lüneborg
Principal 
Conference attendance
Biography

Nanna Lüneborg is a Principal at Novo Ventures, a leading global life science investor, which participated in the IPO of Inventiva in February 2017. Novo Ventures is part of Novo A/S, the holding and investment company of the Novo Nordisk foundation. Prior to joining Novo A/S, she was part of the life science investment team at Apposite Capital, a London-based venture capital firm specialising in healthcare. In 2012, she joined Novo A/S, where she has been part of both the seed and venture investment teams. She has previous board experience from a range of biotech companies spanning start-up to late stage development, most recently from the board of ObsEva, which completed an IPO on NASDAQ in January 2017. She currently serves on the boards of Orphazyme and Epsilon-3 Bio, in addition to Inventiva.

Nanna holds a BA from University of Oxford, a PhD in Neuroscience from University College London as a Wellcome Trust Scholar, and an MBA from University of Cambridge, where she was a Sainsbury Scholar.

Mathias Vinther
Associate 
Conference attendance

Obvislim Ltd.

Presentation Time and Location
on 27th, during Rising Biotech Stars Session (from 14.00 to 16.00)
Company Profile
Obvislim Ltd. is an Israeli Bio-medical startup developing technology that will allow the obese to eat almost whatever they want. The majority of obesity treatments limit the amount/sorts of food consumed by obese patients. This is wrong on a fundamental level, mainly because eating is so much fun. Our Team including physicians and engineers currently is in the POC level and we are searching for seed funding. Our vision is to free obese patients to enjoy food exactly as the non-obese do
Igor Gindin
CEO 
Conference attendance

Oxyprem

Presentation Time and Location
on 25th, during Rising European Stars Session (from 16.15 to 17.15)
Company Website
www.oxyprem.com
Alexander Nitsch
Co-Founder 
Conference attendance
Dr. Stefan Kleiser
Co-Founder 
Conference attendance

Paragate Medical

Presentation Time and Location
on 25th, during Rising Israeli Stars Session (from 15.40 to 16.15}
Company Website
www.paragate-medical.com
Company Profile

Launched in Jan-2016, Paragate Medical is an Israeli innovative startup, aiming to revolutionize the heart failure epidemic management by introducing the first implantable medical device that actively and continuously prevents fluid overload in congestive heart failure patients. The device absorbs systemic extracellular fluid and drains it to the urinary system in a safe and controlled manner.

With its encouraging pre-clinical results and strong IP coverage, the company is currently looking to complete series A to support European based operation towards FIM trials.

Company Type
Keywords

Medical Device, Cardiology, Heart Failure, Minimally invasive implantable, Early Stage

Year Founded
2016
Pipeline Product 1: Name/Stage
Implantable Peritoneal Ultrafiltration / Pre-clinical
Product 1: Description

Paragate's IPU is a minimally invasive, fully implantable device that continuously and actively drains excess systemic extracellular fluid, maintaining fluid overloaded heart failure patients in normal volumes and reducing the need for repeated hospitalizations for acute treatments.

Nitai Hanani
CEO 
Conference attendance
Biography

CEO and Co-founder of Paragate Medical. Over 11 years’ experience in cardiovascular devices field in R&D engineering and management positions, from which 7 with Enopace Biomedical, pioneering the conceptualization and development of intravascular neurostimulation device. Holds B.Sc. in BME from the Technion, resulting in a spinoff startup (Pneumedicare) and an M.Sc. in BME from the Technion-IIT, awarding him with ISHR young investigator award for the research in cardiac resynchronization therapy.

  

PharmaBiome AG

Presentation Time and Location
on 27th, during Rising Biotech Stars Session (from 14.00 to 16.00)
Company Profile
PharmaBiome is a biotechnology company developing a defined microbe-based therapeutics targeting intestinal diseases. We established a platform technology for the development of next generation life biotherapeutics and the implementation of scalable, controllable and efficient solutions, delivering pharmaceutical-grade therapies to the microbiome market.
Tomas de Wouters
CEO 
Conference attendance

Polyneuron Pharmaceuticals AG

Presentation Time and Location
on 27th, during Rising Biotech Stars Session (from 14.00 to 16.00)
Ruben Herrendorff
CEO 
Conference attendance

Portabiles HealthCare Technologies GmbH

Presentation Time and Location
on 25th, during Rising European Stars Session (from 16.15 to 17.15)
Company Website
www.portabiles-hct.de
Company Profile

Portabiles HealthCare Technologies GmbH has been founded in Nürnberg, Germany, in Dec/2016 by an experienced Management and scientific Team: Ralph Steidl (CEO), Prof. Dr. med. Jochen Klucken (University Hospital Erlangen), Prof. Dr. Björn Eskofier (University Erlangen-Nürnberg). The team works closely together since more than seven years and holds extensive competences in the fields of movement disorders, healthcare platforms, wearable technology, machine learning, data mining, and general management.

Company Type
Keywords

gait analysis, wearables, Medical Device, sensors, algorithms, falls prevention,

Year Founded
2016
Financial Summary

We raised in total 645.000 € through shareholder capital, convertible loans, public funding.

For medical device development, approval in Europe and US, and for sales efforts,  another  1 M € are required.

Pipeline Product 1: Name/Stage
Mobile GaitLab
Product 1: Description

Worsening of the human gait is an important symptom in many chronic diseases and reason for most of the falls of elderly. An objective analysis of a patient's gait during activities of daily living delivers valuable information about the progress of a disease, the efficacy of a therapy (or a new drug), and the patient’s individual risk of falling.
Mobile GaitLab consists of motion sensors integrated into the patient's shoes (prepared orthopedic shoes). They measure the gait dynamics and provide clinical grade gait parameters to the therapist (Medical Device class IIa). Doctors thereby will be able to adjust therapy solely based upon those data.
Mobile GaitLab supports clinical trials for proving the efficacy of new drugs, tele-healthcare concepts (e.g. medication adjustment in Parkinson's Disease), and at a later stage prevention of falls. 

Ralph Steidl
Ralph Steidl
CEO 
Conference attendance
Biography

Ralph Steidl, former Managing Director of Astrum IT (a medium sized SW company) has more than 15 years of experience in Management and Sales in IT and Telecommunication Industries and a high level of expertise in Digital Health and Medical Devises Development. He led many interdisciplinary R&D projects dealing with IT-interconnection in Healthcare and clinical grade wearable technologies. 

ResMetrix

Presentation Time and Location
on 25th, during Rising Israeli Stars Session (from 15.40 to 16.15}
Company Profile
Home / Ambulatory monitoring platform that can easily and precisely monitor the lung function, alert the medical provider on deterioration and allow change of treatment at home before Asthma exacerbation. Non invasive accurate monitoring of breathing Recognition of pathologic breathing patterns Breakthrough in Respiratory Care • Novel respiratory disease management technology • Enables non invasive accurate monitoring of breathing • Precise recognition of pathologic breathing patterns • The 4 P’s: Predictive, Personalized, Preemptive, Participatory
Lior Teitelbaum
Lior Teitelbaum
VP Business Development 
Conference attendance
Biography

Mr. Lior Teitelbaum, VP Business Development at MindUP is a healthcare executive with extensive experience in Business Development, Strategy, Scouting and Licensing, Partnering, Portfolio Planning and Strategy and Strategic Alliance Management in the Medical Technology, Pharmaceutical and Biotechnology industries. Prior to joining MindUP Lior was Senior Director of Business Development at BioLineRx LTD, a biopharmaceutical development company, prior to that he served as Director of Business Development at MetaCure, a medical device company focusing on treatment of type 2 diabetes, Prior to that he served as Deal flow and Business Development Manager at Elron Electronic Industries, a technology focused investment company. Lior holds an MBA from the Recanati School of management at Tel Aviv University and an MSc. in molecular genetics from the Weizmann Institute of Science.   

RetiCare IVS

Presentation Time and Location
on 27th, during Rising Biotech Stars Session (from 14.00 to 16.00)
Company Website
not yet available
Company Profile

RetiCare IVS – Setting the sight on new treatments for retinal diseases

RetiCare is a Danish biotech start-up company focusing on developing new neuroprotective treatments for eye disorders. The company has established in-house a highly translational animal model with end-points that are similar to the diagnostic tool applied in human clinical ophthalmology.

The primary focus is on continuing the development of a new peptide treatment with a novel target discovered and characterized by RetiCare’s founders, which induces neuroprotective effects in the retina. The translational setup will also be used to insource and screen new projects with other targets.

Based on existing data and clinical development feasibility the selected initial indication is retinal detachment, but the indication can upon proof-of concept be expanded to include other indications with involvement death of retinal cells such as glaucoma, age-related macula degeneration, diabetic macular edema, and others.

The team behind RetiCare has in combination several decades of experiences within ophthalmological diseases, neuroprotective effects, clinical practice, and life-science entrepreneurship.

 

 

 

Dr. Casper Gøtzsche
Dr. Casper Gøtzsche
Co-founder 
Conference attendance
Morten Albrechtsen
Morten Albrechtsen
Senior Executive 
Conference attendance
Vadim Fedulov
Principal Scientist 
Conference attendance